OBJECTIVE: To improve the quality of organs from brain-dead donors by assessing the influence of alternative strategies on the early behavior of kidneys after transplantation into unmodified hosts. SUMMARY BACKGROUND DATA: Kidneys transplanted from living donors perform consistently better than those from cadaver sources. The authors have recently shown that donor brain death produces inflammatory changes in peripheral organs within hours, amplifies coincident ischemia-reperfusion injury, and accelerates acute and chronic rejection. Normalization of the graft by donor hormone treatment has hitherto been unsuccessful. METHODS: A standardized rat model of brain death was used. Experimental groups included recipients of allogeneic grafts from living and brain-dead donors (F344-->LEW). Donors were treated immediately after induction of brain death either with intravenous steroids, which block inflammatory cytokine release, or a soluble P-selectin glycoprotein ligand (sPSGL), which blocks initial selectin-mediated cellular adhesion. Kidney grafts were examined serially up to 10 days by morphology, immmunohistology, and reverse transcriptase-polymerase chain reaction. RESULTS: Overall survival of ummodified recipients of kidneys from brain-dead donors was significantly reduced versus living donors. Animals with organs from brain-dead donors that had received steroids or sPSGL survived significantly longer than those from untreated brain-dead donors. The intensity of ischemia-reperfusion injury and of acute rejection was reduced. Cellular infiltration and transcription of mRNA of representative proinflammatory mediators were diminished. CONCLUSIONS: Treatment of organ donors at the time of brain death markedly improves organ quality after kidney transplantation, upgrading it to that from a living donor.
OBJECTIVE: To improve the quality of organs from brain-dead donors by assessing the influence of alternative strategies on the early behavior of kidneys after transplantation into unmodified hosts. SUMMARY BACKGROUND DATA: Kidneys transplanted from living donors perform consistently better than those from cadaver sources. The authors have recently shown that donorbrain death produces inflammatory changes in peripheral organs within hours, amplifies coincident ischemia-reperfusion injury, and accelerates acute and chronic rejection. Normalization of the graft by donor hormone treatment has hitherto been unsuccessful. METHODS: A standardized rat model of brain death was used. Experimental groups included recipients of allogeneic grafts from living and brain-dead donors (F344-->LEW). Donors were treated immediately after induction of brain death either with intravenous steroids, which block inflammatory cytokine release, or a soluble P-selectin glycoprotein ligand (sPSGL), which blocks initial selectin-mediated cellular adhesion. Kidney grafts were examined serially up to 10 days by morphology, immmunohistology, and reverse transcriptase-polymerase chain reaction. RESULTS: Overall survival of ummodified recipients of kidneys from brain-dead donors was significantly reduced versus living donors. Animals with organs from brain-dead donors that had received steroids or sPSGL survived significantly longer than those from untreated brain-dead donors. The intensity of ischemia-reperfusion injury and of acute rejection was reduced. Cellular infiltration and transcription of mRNA of representative proinflammatory mediators were diminished. CONCLUSIONS: Treatment of organ donors at the time of brain death markedly improves organ quality after kidney transplantation, upgrading it to that from a living donor.
Authors: J P Turunen; T Paavonen; M L Majuri; S Tiisala; P Mattila; A Mennander; C G Gahmberg; P Häyry; T Tamatani; M Miyasaka Journal: Eur J Immunol Date: 1994-05 Impact factor: 5.532
Authors: D Sako; X J Chang; K M Barone; G Vachino; H M White; G Shaw; G M Veldman; K M Bean; T J Ahern; B Furie Journal: Cell Date: 1993-12-17 Impact factor: 41.582
Authors: W H Hancock; W D Whitley; S G Tullius; U W Heemann; B Wasowska; W M Baldwin; N L Tilney Journal: Transplantation Date: 1993-09 Impact factor: 4.939
Authors: T S Dulkanchainun; J A Goss; D K Imagawa; G D Shaw; D M Anselmo; F Kaldas; T Wang; D Zhao; A A Busuttil; H Kato; N G Murray; J W Kupiec-Weglinski; R W Busuttil Journal: Ann Surg Date: 1998-06 Impact factor: 12.969
Authors: M Takada; K C Nadeau; W W Hancock; H S Mackenzie; G D Shaw; A M Waaga; A Chandraker; M H Sayegh; N L Tilney Journal: Transplantation Date: 1998-06-27 Impact factor: 4.939
Authors: Juan S Danobeitia; Matthew S Hanson; Peter Chlebeck; Elisa Park; Jamie M Sperger; Alice Schwarznau; Luis A Fernandez Journal: Cell Transplant Date: 2014-04-22 Impact factor: 4.064
Authors: F Cicora; P Stringa; D Guerrieri; J Roberti; N Ambrosi; F Toniolo; P Cicora; G Palti; D Vásquez; C Raimondi Journal: Clin Exp Immunol Date: 2012-09 Impact factor: 4.330
Authors: Elisabet Van Loon; Evelyne Lerut; Aleksandar Senev; Maarten Coemans; Jacques Pirenne; Diethard Monbaliu; Ina Jochmans; Mauricio Sainz Barriga; Katrien De Vusser; Amaryllis H Van Craenenbroeck; Ben Sprangers; Marie-Paule Emonds; Dirk Kuypers; Maarten Naesens Journal: Clin J Am Soc Nephrol Date: 2020-08-10 Impact factor: 8.237
Authors: Stacey S Kelpke; Bo Chen; Kelley M Bradley; Xinjun Teng; Phillip Chumley; Angela Brandon; Brett Yancey; Brandon Moore; Hughston Head; Liliana Viera; John A Thompson; David K Crossman; Molly S Bray; Devin E Eckhoff; Anupam Agarwal; Rakesh P Patel Journal: Kidney Int Date: 2012-04-25 Impact factor: 10.612